AGAR T cells / Baylor College of Medicine - LARVOL DELTA

H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Baylor College of Medicine | N=24 ➔ 14

Enrollment change • Hepatocellular Cancer • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3 • IL15

H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2040 ➔ Aug 2040

Enrollment closed • Trial completion date • Hepatocellular Cancer • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2039 ➔ Dec 2040 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Liposarcoma • Nephrology • Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Baylor College of Medicine | Trial primary completion date: Feb 2025 ➔ Oct 2025

Trial primary completion date • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting ➔ Recruiting; Initiation date: Dec 2021 ➔ Jun 2021

Clinical • Enrollment open • Trial initiation date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=27; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine; Initiation date: Jan 2021 ➔ May 2021

Clinical • Trial initiation date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Jul 2039 ➔ Jan 2040; Initiation date: Jul 2020 ➔ Jan 2021; Trial primary completion date: Aug 2024 ➔ Feb 2025

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

Armored CAR T cells safe, clinically active in advanced pediatric liver cancer (Healio) - P1, N=24; NCT04377932; "Steffin and colleges presented interim results of the first three patients — girls aged 3, 7 and 13 years — enrolled and treated with the lowest-level dose (1 × 107 cells/m2) of GPC3 CAR T-cells in the study. Complete safety and treatment response evaluations were available for two of the girls...Results showed no infusion-related or serious adverse events and no dose-limiting toxicities....All three girls had evidence of CAR T cells in peripheral blood, with two showing greater than 40-fold CAR T-cell expansion by the second week after infusion, as revealed by reverse transcription polymerase chain reaction."

P1 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology